NCT02213289 2021-04-08PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond ProgressionUniversity of ChicagoPhase 2 Completed80 enrolled 14 charts
NCT01111604 2019-08-06A Study of Ramucirumab or Icrucumab in Colorectal CancerEli Lilly and CompanyPhase 2 Completed158 enrolled 17 charts